Sigilon Therapeutics, Inc.
SGTX · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Market Cap | $147 | $88 | $1,511 | $732 |
| - Cash | $42 | $107 | $202 | $76 |
| + Debt | $28 | $34 | $37 | $25 |
| Enterprise Value | $133 | $14 | $1,346 | $681 |
| Revenue | $13 | $10 | $13 | $14 |
| % Growth | 34.8% | -28.2% | -5.5% | – |
| Gross Profit | $13 | $10 | $13 | $14 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$39 | -$75 | -$53 | -$42 |
| % Margin | -300.3% | -781.4% | -397.7% | -299.5% |
| Net Income | -$43 | -$78 | -$55 | -$45 |
| % Margin | -335.7% | -815% | -410.3% | -314.9% |
| EPS Diluted | -1.34 | -31.92 | -22.67 | -27.53 |
| % Growth | 95.8% | -40.8% | 17.7% | – |
| Operating Cash Flow | -$51 | -$78 | -$62 | -$50 |
| Capital Expenditures | -$1 | -$2 | -$1 | -$1 |
| Free Cash Flow | -$52 | -$80 | -$63 | -$51 |